Quantinno Capital Management LP Cuts Stock Holdings in Bio-Rad Laboratories, Inc. $BIO

Quantinno Capital Management LP lowered its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,650 shares of the medical research company’s stock after selling 2,585 shares during the quarter. Quantinno Capital Management LP owned approximately 0.13% of Bio-Rad Laboratories worth $9,380,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Massachusetts Financial Services Co. MA raised its stake in Bio-Rad Laboratories by 4,534.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 399,207 shares of the medical research company’s stock worth $120,956,000 after buying an additional 390,593 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Bio-Rad Laboratories by 2,271.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock valued at $111,363,000 after acquiring an additional 380,422 shares during the period. Boston Partners bought a new position in shares of Bio-Rad Laboratories in the 4th quarter worth $75,037,000. Assenagon Asset Management S.A. raised its position in shares of Bio-Rad Laboratories by 6,586.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 147,834 shares of the medical research company’s stock worth $41,209,000 after acquiring an additional 145,623 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth $34,600,000. 65.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BIO has been the subject of several analyst reports. Royal Bank Of Canada assumed coverage on shares of Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 price target for the company. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Weiss Ratings lowered shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Finally, Zacks Research lowered Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Reduce” and an average price target of $303.33.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $332.87 on Wednesday. The company has a 50 day moving average price of $301.02 and a 200 day moving average price of $287.81. The firm has a market capitalization of $8.91 billion, a P/E ratio of 54.84 and a beta of 1.06. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. Bio-Rad Laboratories, Inc. has a 52 week low of $236.73 and a 52 week high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.87. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The company had revenue of $651.00 million for the quarter, compared to the consensus estimate of $623.99 million. During the same quarter in the previous year, the firm earned $2.61 EPS. Bio-Rad Laboratories’s revenue was down .1% compared to the same quarter last year. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 9.14 EPS for the current year.

Trending Headlines about Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Bio-Rad reported second-quarter adjusted earnings of $2.62 per share, exceeding analyst estimates of $1.75–$2.34 and roughly matching the $2.61 earned in the prior-year quarter. Revenue of $651 million also surpassed the approximately $624 million consensus estimate. Bio-Rad Laboratories Beats Q2 Earnings Estimates
• Positive Sentiment: Profitability and liquidity remained supportive: gross profit increased modestly to $345.8 million, operating cash flow was $98.7 million, and cash and equivalents rose to approximately $517 million. A large reported net-income figure was also boosted by items beyond operating performance, making adjusted EPS the more relevant measure for investors. Bio-Rad Laboratories Stock Falls on Q2 2026 Earnings
• Neutral Sentiment: Management’s second-quarter earnings call provided additional detail on the results and outlook, which investors will use to assess demand trends, margins, and execution through the rest of 2026. Bio-Rad Laboratories Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined about 0.1% year over year, while operating profit eased to $72.6 million. The limited top-line growth is a concern because Bio-Rad’s valuation is elevated, with a reported price-to-earnings ratio above 50.
• Negative Sentiment: Bio-Rad guided to fiscal 2026 revenue of $2.5 billion–$2.6 billion, versus consensus of approximately $2.6 billion. The lack of a clearly stated EPS outlook and the lower end of the sales range likely tempered the positive impact of the quarterly earnings beat. Bio-Rad Laboratories Quarterly Earnings Results

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.